2022
Cancer-Associated Hypercalcemia. Reply.
Guise TA, Wysolmerski JJ. Cancer-Associated Hypercalcemia. Reply. New England Journal Of Medicine 2022, 386: 2540. PMID: 35767456, DOI: 10.1056/nejmc2206287.Peer-Reviewed Original ResearchCancer-Associated Hypercalcemia
Guise TA, Wysolmerski JJ. Cancer-Associated Hypercalcemia. New England Journal Of Medicine 2022, 386: 1443-1451. PMID: 35417639, DOI: 10.1056/nejmcp2113128.Peer-Reviewed Original Research
2020
Reply to: Burosumab for Tumor‐Induced Osteomalacia: not Enough of a Good Thing
de Beur S, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO. Reply to: Burosumab for Tumor‐Induced Osteomalacia: not Enough of a Good Thing. Journal Of Bone And Mineral Research 2020, 36: 2455-2456. PMID: 34030212, PMCID: PMC9290665, DOI: 10.1002/jbmr.4317.Peer-Reviewed Original ResearchBurosumab for the Treatment of Tumor‐Induced Osteomalacia
de Beur S, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO. Burosumab for the Treatment of Tumor‐Induced Osteomalacia. Journal Of Bone And Mineral Research 2020, 36: 627-635. PMID: 33338281, PMCID: PMC8247961, DOI: 10.1002/jbmr.4233.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedFibroblast Growth Factor-23Fibroblast Growth FactorsHumansOsteomalaciaParaneoplastic SyndromesQuality of LifeConceptsTumor-induced osteomalaciaCutaneous skeletal hypophosphatemia syndromeSerious adverse eventsAdverse eventsWeek 144Week 48Serum phosphorusTreatment-related adverse eventsFibroblast growth factor 23Surface/bone surfaceAcceptable safety profileOsteoid surface/bone surfacePhase 2 studyGrowth factor 23Phosphaturic mesenchymal tumorTransiliac bone biopsiesHuman monoclonal antibodyMineralization lag timePhosphate metabolismQuality of lifeDose titrationFactor 23Safety profileMesenchymal tumorsSkeletal healthTargeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia
Hartley IR, Miller CB, Papadakis GZ, Bergwitz C, Del Rivero J, Blau JE, Florenzano P, Berglund JA, Tassone J, Roszko KL, Moran S, Gafni RI, Isaacs R, Collins MT. Targeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia. New England Journal Of Medicine 2020, 383: 1387-1389. PMID: 32905668, PMCID: PMC7561341, DOI: 10.1056/nejmc2020399.Peer-Reviewed Original ResearchMeSH KeywordsAgedChondrosarcoma, MesenchymalDisease ProgressionFatal OutcomeFibroblast Growth Factor-23Fibroblast Growth FactorsHumansMaleMolecular Targeted TherapyNeoplasms, Connective TissueOsteomalaciaParaneoplastic SyndromesPhenylurea CompoundsPositron Emission Tomography Computed TomographyPyrimidinesReceptor Protein-Tyrosine KinasesReceptor, Fibroblast Growth Factor, Type 1
2019
A systematic review of paraneoplastic syndromes associated with thymoma: Treatment modalities, recurrence, and outcomes in resected cases
Zhao J, Bhatnagar V, Ding L, Atay SM, David EA, McFadden PM, Stamnes S, Lechtholz-Zey E, Wightman SC, Detterbeck FC, Kim AW. A systematic review of paraneoplastic syndromes associated with thymoma: Treatment modalities, recurrence, and outcomes in resected cases. Journal Of Thoracic And Cardiovascular Surgery 2019, 160: 306-314.e14. PMID: 31982129, DOI: 10.1016/j.jtcvs.2019.11.052.Peer-Reviewed Original Research
2018
Phosphaturic mesenchymal tumors: what an endocrinologist should know
Boland J, Tebben P, Folpe A. Phosphaturic mesenchymal tumors: what an endocrinologist should know. Journal Of Endocrinological Investigation 2018, 41: 1173-1184. PMID: 29446010, DOI: 10.1007/s40618-018-0849-5.Peer-Reviewed Original ResearchConceptsTumor-induced osteomalaciaPhosphaturic mesenchymal tumorMesenchymal tumorsCase of tumor-induced osteomalaciaRare cause of osteomalaciaPhosphaturic hormone fibroblast growth factor 23Recurrent genetic eventsHormone fibroblast growth factor 23Renal phosphate wastingFibroblast growth factor 23Autocrine/paracrine signaling loopTubular phosphate reabsorptionProgressive muscle weaknessProximal tubular phosphate reabsorptionConstellation of symptomsMolecular genetic aspectsBone painCalcitriol therapyCurative surgeryOncogenic osteomalaciaOffending tumorRare causeSurgical removalClinical featuresPrimary treatment
2017
Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database
Padda SK, Yao X, Antonicelli A, Riess JW, Shang Y, Shrager JB, Korst R, Detterbeck F, Huang J, Burt BM, Wakelee HA, Badve SS. Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database. Journal Of Thoracic Oncology 2017, 13: 436-446. PMID: 29191778, PMCID: PMC5983900, DOI: 10.1016/j.jtho.2017.11.118.Peer-Reviewed Original ResearchConceptsThymic epithelial tumorsIndependent prognostic factorOverall survivalPrognostic factorsPrognostic roleRetrospective databaseCox proportional hazards modelKaplan-Meier methodRecurrence-free survivalProportional hazards modelParaneoplastic syndromeCumulative incidenceResection statusTotal thymectomyMyasthenia gravisThymic malignanciesHistologic typeSyndrome statusFemale sexTreatment characteristicsEpithelial tumorsHazards modelLower CIRSyndromeMultivariate analysisReactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome
Weed J, Ko C, Stahl M, Much M, Witt D, Zeidan AM, Leventhal J. Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome. Annals Of Hematology 2017, 96: 1037-1039. PMID: 28220192, DOI: 10.1007/s00277-017-2954-5.Peer-Reviewed Case Reports and Technical NotesRheumatologic Manifestations of Hematologic Neoplasms.
Wang A, Brunet CM, Zeidan AM. Rheumatologic Manifestations of Hematologic Neoplasms. Current Rheumatology Reviews 2017, 13: 51-58. PMID: 27527358, DOI: 10.2174/1573397112666160815125148.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRheumatologic manifestationsBiology of inflammationHematologic neoplasmsParaneoplastic phenomenonPossible underlying pathogenesisPrimary rheumatologic diseasesCommon clinical featuresRheumatologic diseasesClinical featuresAvailable peer-reviewed literatureUnderlying pathogenesisHematologic malignanciesCommon syndromeNeoplasmsDiverse syndromesPathogenesis
2016
Skin manifestations of endocrine and neuroendocrine tumors
Leventhal JS, Braverman IM. Skin manifestations of endocrine and neuroendocrine tumors. Seminars In Oncology 2016, 43: 335-340. PMID: 27178685, DOI: 10.1053/j.seminoncol.2016.02.022.Peer-Reviewed Original Research
2013
Calcinosis in Adult-Onset Dermatomyositis: Metastatic or Dystrophic?
Ladizinski B, Khan A, Sankey C. Calcinosis in Adult-Onset Dermatomyositis: Metastatic or Dystrophic? Journal Of General Internal Medicine 2013, 29: 246-247. PMID: 23943420, PMCID: PMC3889946, DOI: 10.1007/s11606-013-2564-4.Peer-Reviewed Case Reports and Technical Notes
2011
Case 33-2011 — A 56-Year-Old Man with Hypophosphatemia
Bergwitz C, Collins MT, Kamath RS, Rosenberg AE. Case 33-2011 — A 56-Year-Old Man with Hypophosphatemia. New England Journal Of Medicine 2011, 365: 1625-1635. PMID: 22029985, PMCID: PMC4907641, DOI: 10.1056/nejmcpc1104567.Peer-Reviewed Original Research
2010
Management of Carcinoid Tumors
Detterbeck FC. Management of Carcinoid Tumors. The Annals Of Thoracic Surgery 2010, 89: 998-1005. PMID: 20172187, DOI: 10.1016/j.athoracsur.2009.07.097.Peer-Reviewed Original ResearchConceptsAtypical carcinoidCarcinoid tumorsBronchopulmonary carcinoidsParenchyma-sparing techniquesMainstay of treatmentN2 involvementNodal enlargementMediastinal nodesMultimodality treatmentClinical presentationDistant metastasisCentral tumorsHigh suspicionSurgical interventionStaging testsTypical carcinoidModerate suspicionCarcinoidsYounger ageTumorsMediastinoscopySignificant proportionTreatmentSuspicionCell types
2007
Bazex syndrome (acrokeratosis paraneoplastica)
Poligone B, Christensen SR, Lazova R, Heald PW. Bazex syndrome (acrokeratosis paraneoplastica). The Lancet 2007, 369: 530. PMID: 17292773, DOI: 10.1016/s0140-6736(07)60240-2.Peer-Reviewed Original Research
2004
Paraneoplastic Limbic Encephalitis: Ovarian Cancer Presenting as an Amnesic Syndrome
Bloch MH, Hwang WC, Baehring JM, Chambers SK. Paraneoplastic Limbic Encephalitis: Ovarian Cancer Presenting as an Amnesic Syndrome. Obstetrics And Gynecology 2004, 104: 1174-1177. PMID: 15516442, DOI: 10.1097/01.aog.0000128110.31784.c8.Peer-Reviewed Original ResearchMeSH KeywordsAmnesiaBiopsy, NeedleCombined Modality TherapyCystadenocarcinoma, PapillaryDiagnosis, DifferentialFemaleFollow-Up StudiesHumansImmunohistochemistryImmunotherapyLimbic EncephalitisMiddle AgedNeoplasm StagingOvarian NeoplasmsOvariectomyParaneoplastic SyndromesPlasmapheresisRisk AssessmentTreatment OutcomeConceptsParaneoplastic limbic encephalitisShort-term memory lossLimbic encephalitisOvarian cancerMemory lossInitiation of plasmapheresisLimbic system abnormalitiesRare neurologic manifestationDramatic clinical improvementPrompt surgical managementTomography scan findingsEpithelial ovarian cancerClinical improvementNeurologic manifestationsRare complicationScan findingsSurgical managementOvarian tumorsPrimary tumorTesticular cancerSystem abnormalitiesEncephalitisAmnesic syndromeCancerPlasmapheresis
2001
Autoimmunity to βIV spectrin in paraneoplastic lower motor neuron syndrome
Berghs S, Ferracci F, Maksimova E, Gleason S, Leszczynski N, Butler M, De Camilli P, Solimena M. Autoimmunity to βIV spectrin in paraneoplastic lower motor neuron syndrome. Proceedings Of The National Academy Of Sciences Of The United States Of America 2001, 98: 6945-6950. PMID: 11391009, PMCID: PMC34458, DOI: 10.1073/pnas.121170798.Peer-Reviewed Original ResearchMeSH KeywordsAutoantibodiesAutoimmunityBreast NeoplasmsFemaleG(M1) GangliosideHumansMolecular WeightMotor Neuron DiseaseNerve Tissue ProteinsParaneoplastic SyndromesSpectrinConceptsLower motor neuron syndromeMotor neuron syndromeParaneoplastic neurological disordersAxons of motoneuronsSevere neurological diseaseAxon initial segmentNodes of RanvierAutoimmune pathogenesisAutoimmune targetNeurological symptomsBreast cancerPartial improvementNeurological diseasesAffected neuronsNeurological disordersSyndromeAutoantibodiesCancer removalCancer cellsBetaIV spectrinAutoimmunityMajor targetSurface epitopesPathogenesisAxons
1998
Stiff-man syndrome in a woman with breast cancer
Rosin L, DeCamilli P, Butler M, Solimena M, Schmitt H, Morgenthaler N, Meinck H. Stiff-man syndrome in a woman with breast cancer. Neurology 1998, 50: 94-98. PMID: 9443464, DOI: 10.1212/wnl.50.1.94.Peer-Reviewed Original Research
1995
Bazex syndrome: acrokeratosis paraneoplastica.
Bolognia J. Bazex syndrome: acrokeratosis paraneoplastica. Seminars In Cutaneous Medicine And Surgery 1995, 14: 84-9. PMID: 7640201, DOI: 10.1016/s1085-5629(05)80002-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAcrodermatitisEsophageal NeoplasmsFemaleHumansHyperpigmentationLaryngeal NeoplasmsMaleMiddle AgedOropharyngeal NeoplasmsParaneoplastic SyndromesSyndromeConceptsAcrokeratosis paraneoplasticaSkin lesionsUnderlying neoplasmBazex syndromeAdequate clinical descriptionUpper aerodigestive tractSquamous cell carcinomaCutaneous manifestationsPersistent diseaseCutaneous signsAerodigestive tractParaneoplastic naturePsoriasiform lesionsCell carcinomaClinical descriptionLesionsPatientsNeoplasmsDiagnosisSyndromeTumorsDiseaseCarcinomaRecurrenceMalignancy
1994
Unique and Uncommon Skin Signs of Systemic Diseases
Braverman I. Unique and Uncommon Skin Signs of Systemic Diseases. The Journal Of Dermatology 1994, 21: 929-934. PMID: 7868764, DOI: 10.1111/j.1346-8138.1994.tb03314.x.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply